Global Cord Blood Corporation
CORBFOTCHealthcare● Active
$0.95
+$0.00(+0.00%)
Market Cap$127218975
P/E Ratio—
52W High$1.75
52W Low$0.2
Global Cord Blood Corporation (CORBF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CORBF · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2022-03 | 2021-03 | 2020-03 | 2019-03 | 2018-03 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.24B | $1.16B | $1.22B | $0.99B | $0.94B |
| Cost of Revenue | $0.18B | $0.18B | $0.19B | $0.19B | $0.18B |
| Gross Profit | $1.06B | $0.98B | $1.03B | $0.80B | $0.76B |
| Gross Margin %(computed) | 85.26% | 84.57% | 84.52% | 81.15% | 80.63% |
| Operating Expenses | |||||
| R&D Expenses | $0.02B | $0.02B | $0.02B | $0.01B | $0.01B |
| G&A Expenses | $0.19B | $0.17B | $0.19B | $0.17B | $0.24B |
| Total Operating Expenses | $0.45B | $0.44B | $0.47B | $0.42B | $0.48B |
| Operating Income | $0.61B | $0.54B | $0.56B | $0.38B | $0.28B |
| Operating Margin %(computed) | 48.97% | 46.99% | 45.77% | 38.68% | 29.88% |
| Interest Income | $0.03B | $0.03B | $0.03B | $0.03B | $0.02B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | $0.63B | $0.61B | $0.58B | $0.36B | $0.30B |
| Income Tax Expense | $0.12B | $0.09B | $0.10B | $0.06B | $0.06B |
| Net Income | $0.50B | $0.51B | $0.47B | $0.29B | $0.24B |
| Net Margin %(computed) | 40.30% | 43.83% | 38.54% | 29.50% | 25.31% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $4.12 | $4.18 | $3.87 | $2.40 | $1.99 |
| Wtd Avg Shares | 0.12B | 0.12B | 0.12B | 0.12B | 0.12B |
| EBITDA | $0.66B | $0.59B | $0.61B | $0.43B | $0.35B |
| EBITDA Margin %(computed) | 52.83% | 51.22% | 49.82% | 43.98% | 37.75% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · CNY · B
Explore more Global Cord Blood Corporation data
About Global Cord Blood Corporation (CORBF) Income Statement
Global Cord Blood Corporation (CORBF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2022, CORBF reported revenue of $1.24B, gross profit of $1.06B (gross margin 85.26%), and net income of $0.50B — a net profit margin of 40.30%.
Frequently asked questions
CORBF · 4 questionsGlobal Cord Blood Corporation (CORBF) reported revenue of $1.24B for 2022, up 7.2% year-over-year.
CORBF revenueCORBF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09